Loading the section…
We use cookies to keep the site working and to understand which materials are useful. Which cookies · Data processing policy.
iPROMOMED (PRMD): profit is not backed by cash, cash flow to profit −1.50×. No dividends are paid. The debt load is moderate, net debt / EBITDA 1.44×. Data as of 23/10/2026.
Answers to 3 of 4 questions · The analysis is assembled by a program from the data on this page
This section reads the financial statements only; it does not assess market, industry or sanctions risks.
Does the company pay dividends regularly and can it afford the payout
Our payout history has no dividends for this security.
How large the company's debt is relative to its earnings
The debt load is moderate: the ratio of net debt to EBITDA is 1.44×. Over the year the debt load fell; the change is −0.63×. The sector median is 0.25×: the company's debt load is above it.
Data as of 23/10/2026
Is the company's profit backed by real cash
The ratio of free cash flow to net income is −1.50×: the reported profit is hardly confirmed by cash. In money terms, that is RUB −185.24 m of cash flow against profit of RUB 123.45 m.
Data as of 23/10/2026
P/E · IFRS · Price as of 23/10/2026; ratios from the 2025 annual report
Based on the current price and the 2025 annual report, P/E is 12.29×. The valuation history is still too short to compare the share with its own past: observations: 1.
By report year — at the price on the day each year's report came out. The minimum, maximum, median and number of observations are taken over the earlier years: the last year in this list is not part of them
P/E
The share has not had a similar valuation in its history yet.
A similar valuation means P/E within a quarter of the current value. Each year's price is taken the following spring, once the annual report is known; the price change runs between those dates of adjacent years and excludes dividends. The share count used is the current one. This describes the past and is not a forecast.
No dividends are paid.
The debt load is moderate, net debt / EBITDA 1.44×.
Based on the current price and the 2025 annual report, P/E is 12.29×. The valuation history is still too short to compare the share with its own past: observations: 1.
The company's statements do not hold enough data for these questions yet:
What date the figures on this page are as of
The analysis is built on the issuer's published financial statements and disclosures. It is information, not investment advice.